Medical emergencies

Capricor Announces Joint Publication with the US Army Institute of Surgical Research for Cardiosphere-Derived Exosomes as a Potential Therapeutic for Shock

Retrieved on: 
Wednesday, August 4, 2021
Branches of biology, Medical emergencies, Acute pain, Traumatology, Vesicles, Cells, Extracellular vesicle, Vesicle, Major trauma, Coagulopathy, Injury, Shock

LOS ANGELES, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (“Capricor” or “the Company”) (NASDAQ: CAPR), a biotechnology company focused on developing transformative cell and exosome-based therapeutics for treating and preventing a broad spectrum of diseases, announced today the publication, of a manuscript, which shows that cardiosphere-derived exosomes (CDC-EVs) can attenuate kidney damage and promote new blood vessel formation in a preclinical model of acute trauma, both of which are important factors in post-shock recovery. The publication titled, “Extracellular vesicles derived from cardiosphere-derived cells as a potential antishock therapeutic” was published in the international peer-reviewed journal, The Journal of Trauma and Acute Care Surgery in collaboration with researchers at the United States Army Institute of Surgical Research (USAISR).

Key Points: 
  • The publication titled, Extracellular vesicles derived from cardiosphere-derived cells as a potential antishock therapeutic was published in the international peer-reviewed journal, The Journal of Trauma and Acute Care Surgery in collaboration with researchers at the United States Army Institute of Surgical Research (USAISR).
  • The military continues to look for therapeutics that can be delivered in the field to stabilize wounded warriors.
  • While cell therapy held promise in that arena, a lyophilized product that does not require ultra-cold storage is preferable.
  • The goal of the study was to determine the therapeutic potential of CDC-EVs in a rat model of acute traumatic coagulopathy induced by polytrauma and hemorrhagic shock.

Acutus Medical to Participate at the 6th Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference

Retrieved on: 
Tuesday, August 3, 2021
Medical emergencies, Arrhythmia, Cardiac electrophysiology, Heart

CARLSBAD, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (Acutus) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that its management team will attend investor meetings at the 6th Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference on Tuesday, August 17, 2021.

Key Points: 
  • CARLSBAD, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (Acutus) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that its management team will attend investor meetings at the 6th Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference on Tuesday, August 17, 2021.
  • Acutus Medical is an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated.
  • Acutus is committed to advancing the field of electrophysiology with a unique array of products and technologies which will enable more physicians to treat more patients more efficiently and effectively.
  • Founded in 2011, Acutus is based in Carlsbad, California.

Avive Partners with RapidSOS to Create a New Paradigm for Cardiac Arrest Response

Retrieved on: 
Tuesday, August 3, 2021
Medicine, Medical emergencies, Cardiac arrhythmia, Clinical medicine, Medical specialties, Cardiology, Cardiac arrest, Cardiopulmonary resuscitation, Chain of survival, Emergency medical services, Advanced cardiac life support

Cardiac arrest is one of the leading causes of death outside the hospital globally.

Key Points: 
  • Cardiac arrest is one of the leading causes of death outside the hospital globally.
  • While Cardiopulmonary Resuscitation ("CPR") "buys time," a person in cardiac arrest ultimately needs to receive a shock delivered from an AED to survive.
  • However, the greatest challenge with cardiac arrest emergencies is time, as every minute a person in cardiac arrest goes without receiving a defibrillation shock reduces their chances of survival by 7-10%.
  • Together with our RapidSOS Ready emergency community, RapidSOS is supporting first responders in saving millions of lives annually.

Pneumothorax Treatment Devices Market Insights, Competitive Landscape and Market Forecast Report 2021-2026 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 3, 2021
Medical devices, Health, Medical emergencies, Chest trauma, Pneumothorax

What was the Pneumothorax Treatment Devices market share (%) distribution in 2018 and how it will look like in 2026?

Key Points: 
  • What was the Pneumothorax Treatment Devices market share (%) distribution in 2018 and how it will look like in 2026?
  • What will be the Pneumothorax Treatment Devices market growth till 2026 and what will be the resultant market size in the year 2026?
  • What are the current devices available in the Pneumothorax Treatment Devices market?
  • What are the Pneumothorax Treatment Devices available in the market, their product description, regulatory milestones, product development activities, research and development activities etc.?

MindMics Announces Results from a Clinical Trial of Revolutionary Earbuds Technology -- In-ear Infrasonic Hemodynography - to Achieve Cardiac Arrhythmia Assessment beyond that of ECG

Retrieved on: 
Monday, August 2, 2021
Branches of biology, Medicine, Cardiac arrhythmia, Clinical medicine, Cardiac electrophysiology, Medical emergencies, Atrial fibrillation, Electrocardiography, Arrhythmia, Clinical cardiac electrophysiology, Michel Haïssaguerre

CAMBRIDGE, Mass., Aug. 2, 2021 /PRNewswire/ - MindMics, Inc. reported results from the clinical trial of revolutionary earbuds that make use of a new technology -- in-ear infrasonic hemodynography (IH) - for the monitoring of cardiac arrhythmias, resulting in insights beyond those that have been possible with state-of-the-art ECG monitoring. These results were presented at the Heart Rhythm Society meeting in Boston, July 30, 2021.

Key Points: 
  • The clinical trial for recruiting atrial fibrillation (AF) patients was approved by the institutional review board of The University of South Carolina School of Medicine.
  • Synchronized MindMics In-ear Infrasonic Hemodynography (IH) data and ECG were simultaneously recorded from 15 patients in AF and 15 in SR for 20 minutes.
  • Recruited AF patients were between the ages of 45 years and 90 years and showed a variety of arrhythmias.
  • An oral presentation titled "MindMics: In-ear Infrasonic Hemodynography For Cardiac Arrhythmia Assessment Beyond ECG"was given at the Heart Rhythm Society 2021 Annual Meeting: Bringing the World of EP (Electrophysiology) Together on July 28-31.

Acutus Medical to Announce Second Quarter 2021 Financial Results

Retrieved on: 
Thursday, July 29, 2021
Medical emergencies, Arrhythmia, Heart

CARLSBAD, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (Acutus) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today it will release its financial results for the second quarter of 2021 on Thursday, August 12, 2021.

Key Points: 
  • CARLSBAD, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (Acutus) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today it will release its financial results for the second quarter of 2021 on Thursday, August 12, 2021.
  • In conjunction with the release, Acutus will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.
  • The live webinar of the call may be accessed by visiting the Events section of the Acutus investor relations website at ir.acutusmedical.com.
  • Acutus Medical is an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated.

Vapotherm to Participate in the Canaccord Genuity 41st Annual Growth Conference

Retrieved on: 
Wednesday, July 28, 2021
Health, Medical devices, Technology, Manufacturing, Other Technology, Other Manufacturing, Biotechnology, Medical specialties, Medicine, Clinical medicine, Respiratory therapy, Medical emergencies, Respiratory diseases, Canaccord Genuity, Ventilator, Hypercapnia, Genuity, Respiratory therapist, Vapotherm

Vapotherm, Inc. (NYSE: VAPO), (Vapotherm or the Company), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy products, which are used to treat patients of all ages suffering from respiratory distress, today announced that its management team will be participating in the Canaccord Genuity 41st Annual Growth Conference on Wednesday, August 11, 2021 via webcast.

Key Points: 
  • Vapotherm, Inc. (NYSE: VAPO), (Vapotherm or the Company), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy products, which are used to treat patients of all ages suffering from respiratory distress, today announced that its management team will be participating in the Canaccord Genuity 41st Annual Growth Conference on Wednesday, August 11, 2021 via webcast.
  • Vapotherm, Inc. (NYSE: VAPO) is a publicly traded developer and manufacturer of advanced respiratory technology based in Exeter, New Hampshire, USA.
  • Over 2.8 million patients have been treated with the use of Vapotherm high velocity therapy systems.
  • Vapotherm high velocity therapy is mask-free noninvasive ventilatory support and is a front-line tool for relieving respiratory distressincluding hypercapnia, hypoxemia, and dyspnea.

Children's Hospital of Philadelphia-American Heart Association Collaboration Advances Efforts to Enhance Pediatric Resuscitation Programs in Philadelphia

Retrieved on: 
Wednesday, July 28, 2021
Medical emergencies, Cardiology, Medical specialties, Medicine, Emergency medical services, Health, Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, University of Pennsylvania, Cardiac arrest, Advanced cardiac life support, Children's Hospital Colorado

PHILADELPHIA, July 28, 2021 /PRNewswire/ -- Children's Hospital of Philadelphia (CHOP) and the American Heart Association have announced an enhanced collaboration to advance the next generation of pediatric emergency cardiovascular care and resuscitation practices.

Key Points: 
  • PHILADELPHIA, July 28, 2021 /PRNewswire/ -- Children's Hospital of Philadelphia (CHOP) and the American Heart Association have announced an enhanced collaboration to advance the next generation of pediatric emergency cardiovascular care and resuscitation practices.
  • "This initiative will build upon many years of productive collaboration between our hospital and the American Heart Association to improve the quality of resuscitation practice and cardiac care dedicated exclusively to children," said Madeline Bell, President and CEO of CHOP.
  • The chances of survival after in-hospital pediatric cardiac arrest can range from 29-44% and differs greatly between hospitals2.
  • Children's Hospital of Philadelphia was founded in 1855 as the nation's first pediatric hospital.

AngelMed Announces First Commercial Implantation of Real-Time Heart Attack Warning System

Retrieved on: 
Tuesday, July 27, 2021
Medicine, Medical technology, Branches of biology, Medical emergencies, Biomedical engineering, Prosthetics, Acute coronary syndrome, Syndromes affecting the heart, Implant

Indicated for acute coronary syndrome (ACS) events, including silent heart attacks, The Guardian Systemis the first implantable cardiac detection monitor and patient-warning system.

Key Points: 
  • Indicated for acute coronary syndrome (ACS) events, including silent heart attacks, The Guardian Systemis the first implantable cardiac detection monitor and patient-warning system.
  • Dr. Kaplan is a pioneer of new cardiac technologies and has played a significant role in The Guardian's commercialization.
  • "The first commercial implant of The Guardian marks a pivotal advancement in cardiac care.
  • The device detects impending ACS events, including silent heart attacks, and leads to earlier patient treatment," said Dr. Andrew Kaplan.

Mayo Clinic and nference Study Links Pre-Existing Conditions to Short- and Long-Term COVID-19 Complications

Retrieved on: 
Tuesday, July 27, 2021
Medical specialties, Anatomy, Respiratory system, Acute respiratory distress syndrome, Intensive care medicine, Respiratory physiology, Pleural effusion, Ards, Respiratory distress syndrome, Pleural cavity, Medical emergencies

The researchers found hypertension was the most significant risk factor associated with 10 different complications including pleural effusion, acute respiratory distress syndrome (ARDS), cardiac arrhythmia, and anemia.

Key Points: 
  • The researchers found hypertension was the most significant risk factor associated with 10 different complications including pleural effusion, acute respiratory distress syndrome (ARDS), cardiac arrhythmia, and anemia.
  • "The significance of hypertension as a factor in ARDS, which was not previously known, is quite striking," says Venky Soundararajan, PhD, co-founder and chief scientific officer of nference.
  • Specifically in the case of hypertension patients, healthcare workers should expect more serious short term complications."
  • This indicates an increased need to monitor patients with pre-existing conditions for pleural effusion well beyond the initial period of illness.